Leap Therapeutics (NASDAQ:LPTX) Price Target Lowered to $4.00 at Robert W. Baird

Leap Therapeutics (NASDAQ:LPTXGet Rating) had its target price cut by Robert W. Baird to $4.00 in a report released on Monday morning, Stock Target Advisor reports.

Separately, Raymond James decreased their price objective on Leap Therapeutics from $3.50 to $2.50 and set an outperform rating for the company in a report on Friday, November 11th.

Leap Therapeutics Stock Performance

Shares of LPTX opened at $0.59 on Monday. The stock has a 50 day moving average price of $0.86 and a two-hundred day moving average price of $1.09. The firm has a market capitalization of $58.44 million, a P/E ratio of -1.26 and a beta of 0.61. Leap Therapeutics has a 52 week low of $0.55 and a 52 week high of $3.45.

Hedge Funds Weigh In On Leap Therapeutics

Institutional investors have recently modified their holdings of the business. Integrated Wealth Concepts LLC bought a new position in shares of Leap Therapeutics in the first quarter valued at approximately $26,000. Virtu Financial LLC bought a new position in shares of Leap Therapeutics in the first quarter valued at approximately $35,000. Gyon Technologies Capital Management LP bought a new position in shares of Leap Therapeutics in the first quarter valued at approximately $38,000. Gilman Hill Asset Management LLC grew its holdings in shares of Leap Therapeutics by 80.0% in the second quarter. Gilman Hill Asset Management LLC now owns 22,500 shares of the company’s stock valued at $26,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Private Advisor Group LLC grew its holdings in shares of Leap Therapeutics by 104.5% in the first quarter. Private Advisor Group LLC now owns 22,500 shares of the company’s stock valued at $39,000 after acquiring an additional 11,500 shares in the last quarter. 38.08% of the stock is owned by institutional investors.

Leap Therapeutics Company Profile

(Get Rating)

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers.

Read More

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.